183 related articles for article (PubMed ID: 6734031)
21. Disposition of famotidine in renal insufficiency.
Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
[TBL] [Abstract][Full Text] [Related]
22. [Update on antibiotic therapy. 30) Cefonicid].
di Nola F
Minerva Med; 1985 Apr; 76(16):819-25. PubMed ID: 4000526
[No Abstract] [Full Text] [Related]
23. Pharmacokinetics of cefamandole in patients with renal impairment.
Czerwinski AW; Pederson JA
Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of carumonam in patients with renal insufficiency.
Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
[TBL] [Abstract][Full Text] [Related]
25. Cefsulodin kinetics in renal impairment.
Gibson TP; Granneman GR; Kallal JE; Sennello LT
Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of lomefloxacin in renally compromised patients.
Blum RA; Schultz RW; Schentag JJ
Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
[TBL] [Abstract][Full Text] [Related]
27. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
[TBL] [Abstract][Full Text] [Related]
28. Disposition of guanadrel in subjects with normal and impaired renal function.
Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
[TBL] [Abstract][Full Text] [Related]
29. Disposition of minoxidil in patients with various degrees of renal function.
Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
[TBL] [Abstract][Full Text] [Related]
30. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.
Dudley MN; Shyu WC; Nightingale CH; Quintiliani R
Antimicrob Agents Chemother; 1986 Oct; 30(4):565-9. PubMed ID: 3789691
[TBL] [Abstract][Full Text] [Related]
31. High-performance liquid chromatographic determination of cefonicid in human plasma and urine.
Brendel E; Zschunke M; Meineke I
J Chromatogr; 1985 May; 339(2):359-65. PubMed ID: 4008574
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency.
Kelloway JS; Awni WM; Lin CC; Lim J; Affrime MB; Keane WF; Matzke GR; Halstenson CE
Antimicrob Agents Chemother; 1991 Nov; 35(11):2267-74. PubMed ID: 1803999
[TBL] [Abstract][Full Text] [Related]
33. Microbiological and pharmacokinetic evaluation of cefonicid, a long-acting cephalosporin.
Mini E; Mazzei T; Periti P; Reali EF; Bordonaro P; Balocchini E; Ninu B
Chemioterapia; 1987 Jun; 6(2 Suppl):243-6. PubMed ID: 3509398
[No Abstract] [Full Text] [Related]
34. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
[TBL] [Abstract][Full Text] [Related]
36. Penetration of cefonicid in skin suction blister fluid in healthy volunteers.
Cruciani M; Concia E; Passarella E; Soncini R
Int J Clin Pharmacol Res; 1987; 7(3):225-7. PubMed ID: 3596863
[TBL] [Abstract][Full Text] [Related]
37. Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.
Bliss M; Mayersohn M; Arnold T; Logan J; Michael UF; Jones W
Antimicrob Agents Chemother; 1986 Apr; 29(4):649-53. PubMed ID: 3707113
[TBL] [Abstract][Full Text] [Related]
38. Sotalol kinetics in renal insufficiency.
Blair AD; Burgess ED; Maxwell BM; Cutler RE
Clin Pharmacol Ther; 1981 Apr; 29(4):457-63. PubMed ID: 7471612
[TBL] [Abstract][Full Text] [Related]
39. Elimination kinetics of captopril in patients with renal failure.
Duchin KL; Pierides AM; Heald A; Singhvi SM; Rommel AJ
Kidney Int; 1984 Jun; 25(6):942-7. PubMed ID: 6381858
[TBL] [Abstract][Full Text] [Related]
40. Cefamandole kinetics in uremic patients undergoing hemodialysis.
Gambertoglio JG; Aziz NS; Lin ET; Grausz H; Naughton JL; Benet LZ
Clin Pharmacol Ther; 1979 Nov; 26(5):592-9. PubMed ID: 498702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
